%0 Journal Article
%A Nyssen, Olga. P.
%A Pratesi, Pietro
%A Spinola, Miguel. A.
%A Jonaitis, Laimas
%A Perez-Aisa, Angeles
%A Vaira, Dino
%A Saracino, Ilaria Maria
%A Pavoni, Matteo
%A Fiorini, Giulia
%A Tepes, Bojan
%A Bordin, Dmitry. S.
%A Voynovan, Irina
%A Lanas, Angel
%A Martinez-Dominguez, Samuel. J.
%A Alfaro, Enrique
%A Bujanda, Luis
%A Pabon-Carrasco, Manuel
%A Hernández, Luis
%A Gasbarrini, Antonio
%A Kupcinskas, Juozas
%A Lerang, Frode
%A Smith, Sinead. M.
%A Gridnyev, Oleksiy
%A Leja, Marcis
%A Rokkas, Theodore
%A Marcos-Pinto, Ricardo
%A Mestrovic, Antonio
%A Marlicz, Wojciech
%A Milivojevic, Vladimir
%A Simsek, Halis
%A Kunovsky, Lumir
%A Papp, Veronika
%A Phull, Perminder. S.
%A Venerito, Marino
%A Boyanova, Lyudmila
%A Boltin, Doron
%A Niv, Yaron
%A Matysiak-Budnik, Tamara
%A Doulberis, Michael
%A Dobru, Daniela
%A Lamy, Vincent
%A Capelle, Lisette. G.
%A Trpchevska, Emilijia Nikolovska
%A Moreira, Leticia
%A Cano-Catalia, Anna
%A Parra, Pablo
%A Megraud, Francis
%A O'Morain, Colm
%A Ortega, Guillermo. J.
%A Gisbert, Javier. P.
%A Hp EuReg Investigators
%T Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg)
%D 2023
%@ 2079-6382
%U https://hdl.handle.net/10668/28463
%X The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the "most important" variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013-2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin-clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth-quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin-amoxicillin-metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.
%K Helicobacter pylori
%K clustering
%K phenotyping
%K machine learning
%K treatment
%K eradication
%K Science & Technology
%K Life Sciences & Biomedicine
%~